

1 **Reversing the Thyroid Hormone Mediated Repression of a HSV-1 Promoter through**
2 **Computationally Guided Site Directed Mutagenesis**

3
4 Robert W Figliozzi^{a, b}, Feng Chen^a, and Shaochung V Hsia^{a, b, *}

5 ^aDepartment of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of
6 Maryland Eastern Shore

7 ^bDepartment of Natural Sciences, School of Agriculture and Natural Sciences, University of Maryland
8 Eastern Shore

9 Running title: Thyroid hormone mediated viral gene repression

10 ***Correspondence author:** S. Victor Hsia, vhsia@umes.edu

11 Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of
12 Maryland Eastern Shore

13
14 **Key words:** Herpesvirus, Thyroid Hormone, Differentiation, Transcription Factor, Histone Modification

15
16 **Abbreviation:** HSV-1, Herpes Simplex Virus Type-1; T₃, Thyroid Hormone; qPCR, quantitative
17 Polymerase Chain Reaction; TRβ1, Thyroid Hormone Receptor Beta 1; TRE, Thyroid Hormone Receptor
18 Element; EMSA, Electro Mobility Shift Assay; ChIP, Chromatin Immuno-Precipitation; Sp1, specificity
19 protein 1; RXR, Retinoid X Receptor; H3K9me3, histone H3 lysine 9 tri-methylated; VZV, Varicella
20 Zoster Virus; TK, thymidine kinase; DLuc, Dual Luciferase

21
22 DISCLOSURE STATEMENT: The authors have nothing to disclose.

Thyroid hormone mediated viral gene repression

25 **Abstract**

26 Thyroid hormones (TH or T3) and their DNA binding nuclear receptors (TRs), direct
27 transcriptional regulation in different ways depending on the host cell environment and specific promoter
28 characteristics of TH sensitive genes. This study sought to elucidate the impact on repression of nucleotide
29 sequence/orientation of TR binding sites, TR elements, (TREs) within TH sensitive promoters.
30 Computational analysis of the HSV-1 thymidine kinase (TK) gene TRE bound by TR and RXR revealed a
31 single TRE point mutation sufficient to reverse the TRE orientation. In vitro experiments corroborated that
32 the TRE point mutation exhibited distinct impacts on promoter activity, sufficient to reverse the TH
33 dependent negative regulation in neuro-endocrine differentiated cells. EMSA and ChIP experiments
34 suggest that this point mutation altered the promoter's regulatory mechanism through discrete changes in
35 transcription factor Sp1 and TR occupancy and altered enrichment of repressive chromatin, histone-3-
36 lysine-9-trimethyl (H3K9Me3). Incites relating to this negative TRE (nTRE) mechanism impacts the
37 understanding of other nTREs and TRE mutations associated with TH and herpes diseases.

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Introduction**

52 Thyroid hormones (TH or T₃) and their nuclear receptor family members Thyroid Hormone
53 Receptors (TRs) have the ability to increase and decrease the rate of transcription of target genes (Lazar,
54 1993). These target genes generally contain a thyroid response element, TRE, arrangements of single or
55 multiple DNA hexamers recognized and bound by the DNA binding domain (DBD) of TR (Yen, 2001). A
56 host of criteria such as T₃ binding to TRs, TR isoforms binding to target gene promoter regions as
57 monomers, homo or hetero dimers, and the number of, arrangement and sequence of TREs determine the
58 type of regulation (Yen, 2001). These criteria and their outcomes are extensively studied but still poorly
59 understood for most thyroid hormone sensitive genes, which T₃ decreased the target gene expression.

60 It is generally understood that certain TRE arrangements known as direct repeat fours, DR4, consensus
61 AGGT(C/G)A nnnn AGGT(C/G)A, are bound by a TR and retinoid X receptor (RXR) heterodimer which
62 recruit corepressor complexes to the target genes promoter region which modify the bound histones to
63 repress transcription. When T₃ as a ligand binds to the receptor a conformational change causes the
64 corepressors to leave and be replaced by coactivators that modify the histones to attract the transcription
65 machinery. Alternatively, several TREs with arrangements known as palindromes, often found on genes
66 related to the feedback inhibition of T₃ synthesis, regulate transcription in an opposite manner (Chatterjee
67 et al., 1989). For these negative TREs (nTRE) the un-ligand TR somehow activated gene expression and
68 then conferred repression upon binding T₃ however this type of regulation is not well described possibly
69 due to the conflicting circumstances for different genes that contain similar nTREs. There is argument over
70 whether TR/DNA binding is maintained and what cofactors are involved because there has been evidence
71 to support many different hypotheses depending on the system/cell line and gene being studied.

72 Our previous studies suggested that T₃ participated in the HSV-1 regulation by repressing viral
73 replication and gene expression (Bedadala et al., 2010; Figliozzi et al., 2014; Hsia et al., 2010). The HSV-
74 1 Thymidine Kinase, TK, has been shown to play an intriguing role during reactivation (Kosz-Vnenchak et
75 al., 1993; Nichol et al., 1996; Tal-Singer et al., 1997; Valyi-Nagy et al., 1994; Wilcox et al., 1992) and is
76 one of the thyroid hormone sensitive genes that contains a palindromic nTRE which has seen some debate

Thyroid hormone mediated viral gene repression

77 and intrigue for several decades (Maia et al., 1996; Park et al., 1993). The TK nTRE is in a context of
78 palindrome with 6 nucleotides spacing (Pal6) (Hsia et al., 2010). In undifferentiated non-neuronal cells
79 there is no regulation (Figliozzi et al., 2014; Hsia et al., 2010). However, it appears to result in TK being
80 transcriptionally repressed by T₃ in neuronal cells, evidenced by HSV-1 infection and in transfection
81 reporter assay experiments (Hsia et al., 2010).

82 We have set out to better understand the precise TK nTRE nucleotide and TR/RXR residue
83 interactions that define this protein-DNA binding, using web-based molecular biology applications to steer
84 our benchtop TK nTRE site directed mutagenesis experiments. Performing a point mutation on a
85 computationally identified nucleotide within the TRE, we generated a mutant that exhibited reversal of T₃
86 sensitivity measured by dual luciferase assays. The luciferase reporter system has been used by several labs
87 to evaluate nTREs in a variety of promoters including TSH α , TSH β and HSV-1 TK (Lalli and Sassone-
88 Corsi, 1995; Latif et al., 2016; Shibusawa et al., 2003). Electro-mobility shift assays (EMSA) were used to
89 determine whether TR may exhibit differential binding to the wild type and mutant promoters. Chromatin
90 Immuno-Precipitation (ChIP) Assays were used to determine what effects on the histone modification and
91 SP-1 transcription factor binding that the mutations caused.

92

93 **Experimental Procedures**

94 *Computational analyses of protein-DNA binding*

95 The protein data bank (pdb) file 2NLL which depicts the crystallography structure of the RXR and
96 TR heterodimer bound to a traditional TRE sequence 5'-CAG GTC ATT TCA GGT CAG-3' was
97 manipulated using the Swiss PDB Viewer, SPV, (<http://spdbv.vital-it.ch/>) (Johansson et al., 2012) to obtain
98 2 separate pdb files for each protein monomer bound to a 5'-AGGTCA-3' hexamer TRE half-site. The
99 interaction of TREs and nuclear receptors was computationally analyzed by the web based application
100 PiDNA (<http://dna.bime.ntu.edu.tw/pidn>) (Lin and Chen, 2013). Each monomer-hexamer pdb was used as
101 a template in the PiDNA web application to computationally predict the binding affinities of the monomers
102 to the wild type hexamers and randomly generated single base pair mutant hexamers. A variety of criteria

Thyroid hormone mediated viral gene repression

103 such as energy release index and position frequency matrix analyses. Hydrogen bond interactions between
104 the DNA binding domain residues and hexamer nucleotides were measured using Python Molecule Viewer
105 software (<http://mgltools.scripps.edu/documentation/tutorial/python-molecular-viewer>), Swiss PDB
106 viewer, and PDBSum ([http://www.ebi.ac.uk/thornton-srv/databases/cgi-
107 bin/pdbsum/GetPage.pl?pdbcode=index.html](http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=index.html)) (Johansson et al., 2012). PDBSum calculates all hydrogen
108 bonds between the DNA and the Protein in the pdb files. Hydrogen bonds were predicted using the
109 HBPLUS (<http://www.ebi.ac.uk/thornton-srv/software/HBPLUS/>) default parameters were satisfied. The
110 default parameters H-A distance is < 2.7, D-A distance is < 3.35, and the D-H-A angle is > 90. Schematic
111 diagrams of protein-nucleic acid interactions were created by NUCPLOT ([http://www.ebi.ac.uk/thornton-
112 srv/software/NUCPLOT/](http://www.ebi.ac.uk/thornton-srv/software/NUCPLOT/)) program (Luscombe et al., 1997; Luscombe et al., 1998).

113

114 *Construction of TRE mutant plasmid*

115 The wild-type TK reporter plasmid pGL4.74-hRluc/TK was purchased from Promega (Cat #
116 E6921). The single nucleotide mutation was introduced into the promoter region using Phusion Site-
117 Directed Mutagenesis Kit from Thermo Fisher Scientific (Cat#: F-541) as described by the manufacturer.
118 In short, template plasmid pGL4.74 was used in a PCR reaction using mutagenesis primers with 5'
119 phosphorylation modifications. The PCR reaction resulted in amplified linear point mutated plasmid in its
120 entirety followed by a ligation to cyclize the linear PCR product to form circular plasmid containing single
121 point mutation. The sequence and size of the generated plasmid were confirmed by gel electrophoresis and
122 sequencing. The computational results discussed in a later section and depicted in Fig. 1 led to the
123 development of the forward, 5'-tcgcatattaagggtgccgctgtggc-3', and reverse, 5'-agtggacctgggaccgccc-3',
124 primer used for mutagenesis and strategy depicted in Fig. 2.

125

126

Thyroid hormone mediated viral gene repression

127 *Cells*

128 The human prostate cancer cell line, LNCaP, was obtained from ATCC (Cat#: CRL-1740) and
129 grown in RPMI-1640 supplemented with 10% FBS. Vero cells (ATCC Cat#: CCL-81) were grown in
130 DMEM supplemented with 10% FBS. Cells were grown and maintained at 37 °C and 5% CO₂ in a cell
131 culture incubator.

132

133 *Neuroendocrine differentiation (NED)*

134 The differentiation was achieved by removing androgen from the culture condition. In short,
135 proliferating LNCaP cells were cultured in phenol red-free RPMI 1640 supplemented with 10% charcoal
136 dextran treated FBS. The cells were seeded onto culture dishes at 4.0×10^3 cells per cm² of culture dish
137 growth area. These conditions were maintained for at least 5 days before being treated further. A detailed
138 protocol was reported previously (Figliozzi et al., 2014).

139

140 *Transfection*

141 Lipofectamine 3000 (Cat#: L3000, Life Technologies) was used for transfection of LNCaP
142 cells. Detailed protocol was provided by the manufacturer.

143

144 *Reporter assays*

145 Luciferase activity was measured by a luminometer using the Dual-Luciferase reporter assay
146 system (Cat#: PR-E1910, Promega). The cell lysate was collected for the luciferase assay after 48 h of
147 transfection essentially described by the manufacturer. Luminescence was measured over a 10-s interval
148 with a 2-s delay on the Synergy HTX multi-mode plate reader (Cat#: S1L, Biotek). The renilla luciferase
149 activities were normalized against the internal firefly luciferase control driven by HSV-1 VP16 promoter

Thyroid hormone mediated viral gene repression

150 to correct for transfection efficiency. The results were presented as the percent induction of the reporter
151 plasmid in the presence or absence of T₃ (100 nM).

152

153 *Antibodies*

154 Detailed in Table 1. Anti-TRβ1 antibody was obtained from Thermo-Fisher (Cat#: MA1-215).
155 Anti-RXRα (Cat#: ab41934) and anti-histone H3 tri-methylated K9 (Cat#: ab8898) was procured from
156 Abcam Biotech. Anti-SP1 antibody was purchased from Santa Cruz Biotechnology (Cat#: SC-59).

157

158 *Electro-mobility Shift Assays (EMSA) and protein extraction*

159 EMSA was performed using the LightShift™ Chemiluminescent EMSA Kit (Cat#20148, Fisher
160 Scientific). The manufactures protocol was followed using 3'-biotin modified oligos corresponding to the
161 wild type and TRE1 mutant sequences. The oligos were annealed and incubated with protein extracts from
162 undifferentiated or differentiated LNCaP cells pretreated or without pretreatment of T₃ in binding buffer
163 for 30 min. The binding reaction mixtures were loaded onto 6% DNA Retardation Gel (Cat#: EC6365BOX,
164 Invitrogen) and ran at 100V. The samples were transferred onto positively charged nylon membranes
165 overnight using the capillary method. The membranes were blocked, washed, and exposed per the
166 manufacturer. The membranes were sealed in blotting envelopes and photographed in a Bio-Rad ChemiDoc
167 Imaging system. The sequences of the oligos are TK-Pal6-TRE-for: 5'-TAT TAA GGT GAC GCG TGT
168 GGC CTC GAA CAC CG-3' [BioTEG-Q] and TK-TRE1-mut1; 5'-TAT TAA GGT GCC GCG TGT GGC
169 CTC GAA CAC CG-3' [BioTEG-Q]. Their complementary sequences were synthesized and annealed using
170 protocol described previously (Bedadala et al., 2010).

171 Protein Extracts were prepared from undifferentiated or differentiated LNCaP cells grown in T75s
172 treated overnight with or without T₃. Protein was isolated using RIPA buffer (Thermo Scientific cat# 89900)
173 based on the protocol of the manufacturer. Briefly, the cells were washed twice with cold DPBS and
174 exposed to cold RIPA buffer with Halt protease inhibitor cocktail (Thermo Sci cat# 78410) for 5 min on

Thyroid hormone mediated viral gene repression

175 ice with gentle rocking. The lysate was scraped and collected followed by centrifuging at $14,000 \times g$ for 15
176 minutes to pellet the cell debris. The supernatant was used for EMSA assays.

177

178 *Chromatin Immuno-precipitation (ChIP)*

179 The ChIP was performed using ChromaFlash High-Sensitivity ChIP Kit from Epigentek,
180 Farmingdale, NY (Cat#: P-2027-48). The protocol was described per the manufacturer. In short, test
181 antibodies were first bound to Assay Strip Wells as well as Anti-RNA polymerase II (positive control) and
182 non-immune IgG (negative control). The cells were subjected to cross-linking by adding media containing
183 formaldehyde to a final concentration of 1% with incubation at room temperature (20–25 °C) for 10 min
184 on a rocking platform (50–100 rpm). Glycine (1.25 M) was added to the cross-link solution (1:10) to stop
185 the cross-linking. After appropriate mixing and ice-cold PBS washing and centrifuging, Working Lysis
186 Buffer was added to re-suspend the cell pellet and incubate on ice for 10min. After carefully removing the
187 supernatant, ChIP Buffer CB was added to re-suspend the chromatin pellet. Shear chromatin using Water
188 Bath Sonication (EpiSonic 1100 Station, Cat No. EQC-1100, Epigentek). The program was set up at 20
189 cycles of shearing under cooling condition with 15 s On and 30 s Off, each at 170–190W. ChIP samples
190 were centrifuged at 12,000 rpm at 4 °C for 10min after shearing and transferred supernatant to a new vial.
191 Next set up the reactions by adding the ChIP samples to the wells that are bound with test antibodies,
192 positive control, or negative control. The reaction incubation condition was 4°C overnight. ChIP samples
193 then were washed per the protocol and subjected to reverse cross-linking at 60 °C for 45 min. Finally, the
194 DNA samples were purified by spin column for quantitative PCR (qPCR).

195

196 *ChIP-qPCR*

197 Quantitative analyses of ChIP and gene expression were performed by qPCR using myiQ SYBR
198 green super-mix and iScript One-Step RT-PCR kits (BIO-RAD). Experiments were performed in triplicate
199 with one set of primers per reaction. The ChIP primer sequences for TK TRE are 5'-ATG GCT TCG TAC
200 CCC TGC CAT-3' and 5'-GGT ATC GCG CGG CCG GGT A-3'. The qPCR reactions were carried out at

Thyroid hormone mediated viral gene repression

201 94 °C for 3 min, followed by 30 cycles of 94 °C for 15 s, 69 °C for 15 s, and 72 °C for 15 s. The results
202 were calculated using Percent Input method with pre-immune antibody background subtracted.

203

204 **Results:**

205 *Computer analyses of putative binding of TR to alternative TRE*

206 Swiss PDB Viewer (SPV) was used to generate two pdb files from 2NLL, each with either the
207 DBD of TR β or RXR α bound to its half-site. The generated pdb files were used as inputs for PiDNA.
208 PiDNA randomly mutated the half-sites to yield hexamers with altered RXR or TR occupancy based on
209 increased energy release due to binding and position frequency matrix analyses. PiDNA identified 5'-
210 AGGTGA-3' (TRE-1a) on the positive strand of the wt HSV-1 TK promoter (Fig. 1A) and 5'-AGGCCA-
211 3' (TRE-2) on the reverse strand as the optimal half-sites for protein binding (data not shown). The
212 orientation of these half-sites suggests a palindromic TRE with a six-base pair spacer (Pal 6) as suggested
213 by us and others (Figliozzi et al., 2014; Hsia et al., 2010; Maia et al., 1996; Park et al., 1993). Interestingly,
214 PiDNA also suggested an alternative binding to 5'-GCGTCA-3' (TRE-1b) located at the reverse strand
215 (Fig. 1A). This half-site exhibited the same binding strength in comparison to TRE-1a (data not shown).

216 Computational observations revealed that a TRE-1a 6A/C mutation on the positive strand to
217 become 5'-AAGTGC-3' would create a new TRE-1b' with half-site sequence of 5'-GCGGCA-3' on the
218 reverse strand identified by PiDNA as preferentially bound by RXR in comparison to TRE-1a' (Fig. 1B)
219 (Rastinejad et al., 2013; Rastinejad et al., 1995). Thus, TRE-1b' and TRE-2 would create a pair of direct
220 TRE repeat with three nucleotide spacing, likely to behave as positive TRE conferring positive regulation.
221 PDBSum analysis of TR β and RXR α hydrogen bonding further suggests the likelihood of a direct repeat
222 on the mutant promoter. The mutant TRE1b' would gain one more hydrogen bond from Arg160 from the
223 RXR α (Fig. 1B) to strengthen the interaction which is absent from the wild type.

224

225

226 *Site-directed mutagenesis*

227 HSV-1 TK promoter contains a pair of TREs exhibiting palindrome repeats with six nucleotides
228 separating each other (Pal6 TREs). These Pal6 TREs reside between the TATA box (47933–47937) and
229 the transcription initiation site (47911) (Fig. 2) based on the HSV-1 complete genome sequence accession
230 number X14112. This context was discussed previously to produce negative regulation by T₃ in neural cells
231 but different cells generating different opposite results even in several cells with neural origin (Figliozzi et
232 al., 2014; Hsia et al., 2010; Maia et al., 1996; Park et al., 1993). To address the importance of TRE sequence
233 in the T₃ -mediated negative regulation, a point mutation was introduced followed by reporter assays to
234 study the regulatory effects. For easy discussion, the TRE adjacent to TATA box was named TRE1 and the
235 other one was called TRE2 (Fig. 2). The mutation was introduced to the end of TRE1 from 5'-AGGTGA-
236 3' to 5'-AGGTGC-3' (Fig. 2, mtTRE1). The original TK TRE was named wtPal6. The resulting plasmid
237 mtTRE1 was confirmed by sequencing (data not shown).

238 *TK promoter and its mutant were not regulated by T₃ in undifferentiated LNCaP cells*

239 These reporter plasmids were first tested by dual luciferase (DLuc) assay after transfection of
240 undifferentiated LNCaP cells treated with and without T₃. DLuc assays showed that the T₃ treatment did
241 not affect the promoter activity of any plasmid (Fig. 3A), indicating that there is no T₃ -mediated regulation
242 in undifferentiated cellular environment.

243

244 *TK single nucleotide mutant reporter plasmids exhibited distinct T₃ -mediated regulation in*
245 *differentiated LNCaP cells*

246 The plasmids were later transfected into differentiated LNCaP cells with or without T₃ treatment.
247 Fig. 3B shows T₃ treatment caused a 10-fold reduction in wtPal6 promoter activity, consistent with our
248 previous finding that T₃ mediated a negative regulation in differentiated cellular background. In contrast
249 mtTRE1 activity showed the opposite regulatory profile with a 4-fold increase upon T₃ treatment (Fig. 3B,

Thyroid hormone mediated viral gene repression

250 mtTRE1 panel). In differentiated LNCaP, under T₃ the wt promoter activity was at least 70-fold weaker
251 than mtTRE1 (Fig. 3B). Together these observations demonstrated that single nucleotide changes within
252 the TREs can disrupt the normal T₃ -mediated repression of HSV-1 TK promoter only in differentiated
253 cells.

254

255 *Addition of T₃ to differentiated cells without prior treatment of T₃ reduced its capacity of TR to*
256 *bind wt TREs*

257 The binding of TR to the TREs under the influence of hormone was investigated by EMSA. Wild
258 type promoter oligo and protein extract from differentiated cells not pretreated with T₃ were first tested.
259 Shifted bands were detected where the addition of T₃ slightly reduced the band intensity (compare Fig. 4A,
260 lane 2 and 3). The decreased interaction by T₃ was more significant if longer electrophoresis was allowed
261 (Fig. 4C, lane 2 and 3). These observations demonstrated that proteins from the extract interacted with the
262 TRE oligo and T₃ reduced the binding. To address if TR contributed to the binding to the TRE, antibodies
263 against TR or RXR were introduced in the EMSA. The results showed that the retardation bands were
264 completely abolished upon the addition of anti-TR Ab and only slightly affected upon the addition of anti-
265 RXR Ab (Fig. 4A, lane 4-5 and 6-7, respectively), supporting that TR played a critical role in this
266 interaction, perhaps by direct binding to the TK-TREs with RXR functioning as a partner.

267

268 *TK-TREs were not bound by TR from undifferentiated cells*

269 Protein extract from undifferentiated LNCaP cells of equivalent total protein concentrations used
270 in differentiated extract experiments in Fig. 4A were used to compare the TRE/TR interaction. Surprisingly
271 the strong interaction between wtTRE and TR from differentiated cells (Fig. 4B, lane 8) was not observed
272 (Fig. 4B, lane 1-7) even though TR is detectable at this dilution (data not shown). The mutant TRE oligo
273 yielded similar results of no interaction (Fig. 4B, lane 9-15). Previous study indicated that TR β was

Thyroid hormone mediated viral gene repression

274 expressed in undifferentiated LNCaP cells (Figliozzi et al., 2014). This results suggested that differentiated
275 status played critical roles in TR binding to TK TREs.

276

277 *Interaction of T₃ to TR of differentiated cells pretreated with T₃ increased its binding capacity to*
278 *wt TREs*

279 To mimic the physiological condition, we pretreated differentiated LNCaP cells with T₃ for 48
280 hours and wash the cells with PBS followed by protein extraction (prior T₃ pretreatment). It was noted that
281 T₃-pretreated protein extracts caused the band intensity to increase upon T₃ addition (compare Fig. 4C,
282 lane 4 and 5). Upon addition of anti-TR Ab, the lane lacking T₃ binding treatment nearly disappeared (Fig.
283 4C, lane 6) whereas its T₃ treated counterpart band was still clearly visible with reduced intensity (Fig. 4C,
284 lane 7), suggesting that ligand TR, if pretreated with hormone, exhibited a stronger binding capacity to
285 TREs. The addition of anti-RXR Ab had little effect on these bands (Fig. 4C, Lane 8 and 9).

286

287 *mtTRE1 demonstrated different pattern of binding in comparison to wt TREs*

288 TRE mutants were investigated for their binding by TR. It was shown that mtTRE1 band intensity
289 decreased to very low level in the presence of T₃ (compare Fig. 4D, lane 2 and 3), similar to the pattern of
290 no prior T₃ treatment (compare Fig. 4A, lane 2 and 3). Anti-TR Ab experiments again suggested that this
291 interaction required TR (Fig. 4D, lane 4 and 5). Unlike the wtTRE, the addition of anti-RXR Ab also
292 reduced the band signal, which suggested that RXR was also involved in DNA binding on the mtTRE (Fig.
293 4C, Lane 6 and 7). Together these observations suggested that the mutation disrupted the interaction of
294 nuclear hormone receptors to the wild-type TRE thus altering the negative regulation.

295

296 *Repressive chromatin H3K9me3 enriched at wt promoter in the presence of T₃ was released in*
297 *mtTRE1 promoter*

Thyroid hormone mediated viral gene repression

298 ChIP was performed to investigate the impact of single nucleotide change of the TREs on the
299 chromatin recruitment to the promoter. In this experiment using an antibody against H3K9me3, a repressive
300 histone previously reported to be associated with TK promoter with T₃ (Figliozzi et al., 2014), we showed
301 that in the wt promoter the tri-methylated histone interaction was increased 4.3-fold upon T₃ addition (Fig.
302 5A), in agreement with our hypothesis that T₃ mediated repression in differentiated cells. In contrast the
303 opposite effect was shown for the mtTRE1, where H3K9me3 recruitment decreased by as many as 5.5-fold
304 in the presence of T₃ (Fig. 5A). This result indicated that one nucleotide mutation shifted the histone profile
305 under the same condition.

306

307 *Transcription factor Sp1 occupancy was reversed by TRE sequence changes*

308 Recruitment of transcription factor was studied by ChIP Assays using antibodies against Sp1. It
309 was revealed that Sp1 recruitment to the wt promoter increased 4-fold without T₃, whereas decreased
310 approximately 3-fold in the mtTRE1 promoter (Fig. 5B). There are two Sp1 binding sites, -111 and -59 bp,
311 respectively (Coen et al., 1986) and they did not overlap with TK TREs. This observation suggested that
312 mutant TREs may alter chromatin configuration therefore influence the interaction of transcription factor
313 to its binding sites.

314

315 **Discussion:**

316 Seemingly minute TRE sequence differences in promoters would direct chromatin recruitment and
317 determine the type of T₃ -mediated regulation. However, the mechanisms are poorly understood. Putative
318 TREs were identified within a wide variety of promoters and characterized as *bona fide* TREs by molecular
319 analyses. Several TREs were depicted in viral promoters including HSV-1 TK (Bedadala et al., 2010;
320 Desai-Yajnik and Samuels, 1993; Desvergne and Favez, 1997; Hsia et al., 2011; Hsia and Shi, 2002; Hsia
321 et al., 2003; Hsia et al., 2001; Zuo et al., 1997). For decades the HSV-1 TK promoter has been used as a
322 transcriptional control and studied for its T₃ sensitivity (Maia et al., 1996). Bioinformatics demonstrated a
323 pair of nontraditional palindromic TK TREs located between TATA box and the transcription initiation

Thyroid hormone mediated viral gene repression

324 site, in a context like the thyroid stimulating hormone alpha (TSH α) TREs, one of the most well
325 characterized negative TREs (Carr et al., 1992; Hollenberg et al., 1995; Jacobs and Kuhn, 1992; Kohn et
326 al., 1992; Rentoumis et al., 1990). It is thus hypothesized that TK TREs would be bound by TR/T₃ to confer
327 negative regulation in differentiated cells with neural phenotype but not non-neural cells (Hsia et al., 2010;
328 Park et al., 1993). Nonetheless it is quite complicated. First it was shown that TR/T₃ exhibited no regulation
329 of TK transcription on most of the non-neural cells (Hsia et al., 2011; Maia et al., 1996) but generated good
330 negative regulation in differentiated mouse neuroblastoma cells N2a (Hsia et al., 2010). These observations
331 supported the hypotheses nicely. However, more studies indicated that there was no T₃-mediated regulation
332 in rat pituitary GH4C1 cells (Park et al., 1993), a popular model to investigate molecular mechanisms of
333 TRH receptor function, signal transduction, electrophysiological studies on plasma membrane calcium
334 channels, and intracellular calcium homeostasis in pituitary cells. Nevertheless, it appeared that TR/T₃
335 delivered negative regulation in human choriocarcinoma cell line JEG-3, a placental epithelial-trophoblast-
336 like cells had little evidence of differentiation (Maia et al., 1996). Furthermore, HSV-1 TK was negatively
337 regulated by T₃ in a differentiated but not a true neural cells LNCaP cells (Figliozzi et al., 2014). Together
338 these statements suggested that T₃-mediated regulation on a promoter with palindromic TREs may be
339 controlled by multiple factors such as cell origin, host regulatory protein recruitment, TRE sequence
340 composition/context, nuclear receptor subtypes, dimerization preferences, differentiation status, and
341 chromatin context.

342 The negative regulation of T₃ and TR is not as well-characterized as the positive regulation but is
343 of equal importance. A number of hypotheses have been suggested such as suppression of Sp1 stimulation
344 (Xu et al., 1993), cAMP response element binding (CREB) competition (Mendez-Pertuz et al., 2003),
345 recruitment of chromatin insulator protein CTCF (Burke et al., 2002), the downstream binding to TATA
346 box and direct interaction of TFIID (Crone et al., 1990), hetero- to homodimer conformational alteration
347 (Bendik and Pfahl, 1995), interaction of GATA2 and TRAP220 dissociation (Matsushita et al., 2007),
348 TR/Sp1 competition in the first exon (Villa et al., 2004), ligand-mediated recruitment of histone
349 deacetylases (HDAC) complex (Sasaki et al., 1999), interaction of TR/TATA binding protein (TBP) and

Thyroid hormone mediated viral gene repression

350 HDAC (Sanchez-Pacheco and Aranda, 2003), and conversion of corepressor SMRT to coactivator by TR
351 (Berghagen et al., 2002). It is being debated that if T_3 -mediated negative regulation required TR-DNA
352 binding (Madison et al., 1993; Shibusawa et al., 2003; Tagami et al., 1999). In this study, another layer of
353 complication, differentiation, was added to the sophisticated regulation. It is known that T_3 induces
354 differentiation in several different tissues of many different species (Nygard et al., 2003). Studies suggested
355 that T_3 induced withdrawal from the cell cycle through S-phase genes inhibition such as E2F1, S-phase-
356 specific DNA polymerase alpha, thymidine kinase, and dihydrofolate reductase genes. For instance,
357 ligand TR triggered differentiation by suppressing E2F-1 gene expression, a key transcription factor that
358 controls G1- to S-phase transition (Nygard et al., 2003). It is surprising to learn that differentiated cells with
359 prior treatment of T_3 exhibited stronger TR binding capacity to wtTRE in the presence of T_3 . The exact
360 mechanisms are not understood. It is likely that prior exposure to T_3 changed the gene expression profiles
361 to modulate the TR/TRE interaction. It cannot be ruled out that differentiated and undifferentiated
362 conditions generated distinct chromatin environments allowing these discrete interactions.

363 The occupancy of transcription factor Sp1 to the TK promoters with different TREs was assessed.
364 The ChIP results matched the DLuc assays and indicated that Sp1 occupancy promoted active transcription
365 in the absence of T_3 (compare Fig. 3B and Fig. 5B). It is worth noting that in the presence of T_3 , Sp1
366 recruitment to mtTRE1 was enhanced by 16-fold in comparison to wtTRE (Fig. 5B). It seemed that Sp1
367 binding was determined, at least in part, by TR binding (compare Fig. 5B to Fig. 4C and 3D) and the ligand
368 appeared to play a critical role. Position weight matrix comparison of the wild type and mutant promoter
369 for Sp1 binding sites did not reveal additional sites upon mutation (data not shown). Two Sp1 binding sites
370 are not found overlapping the TK TRE but well upstream of the TATA box (-111 bp and -59 bp), therefore
371 the mutations did not affect the Sp1 binding site but still altered its binding profile (Coen et al., 1986). It is
372 unclear how the mutation achieved this phenomenon. We therefore speculate that in both cases T_3
373 modulated histone modification and the resulting chromatin environment at this promoter determined Sp1
374 occupancy.

Thyroid hormone mediated viral gene repression

375 HSV-1 TK is not essential during lytic infection (Coen et al., 1986; Knipe and Howley, 2013)
376 however it plays a critical role in the drug action of acyclovir and reactivation (Kosz-Vnenchak et al., 1993;
377 Nichol et al., 1996; Tal-Singer et al., 1997; Valyi-Nagy et al., 1994; Wilcox et al., 1992). In resting cells
378 such as neurons dNTPs are absent and requires TK action to provide dNTPs for viral replication (Knipe
379 and Howley, 2013). In contrast to the lytic infection that viral replication is not essential for α and β gene
380 expressions, TK was suggested to promote replication followed by efficient α and β gene expressions in
381 neurons during reactivation to complete the life cycle (Nichol et al., 1996; Tal-Singer et al., 1994). In
382 addition, TK null mutant showed decreased viral gene expression upon reactivation (Kosz-Vnenchak et al.,
383 1993) and in vivo reactivation studies revealed that TK was among the first genes to be expressed (Pesola
384 et al., 2005; Tal-Singer et al., 1994).

385 In conclusion, the unique negative TREs of HSV-1 TK were characterized in this report by side-
386 directed mutagenesis. T_3 was not sufficient to control TK promoter activity in undifferentiated condition
387 but conferred repression while cells were differentiated. A point mutation at TRE1 close to TATA box
388 changed the T_3 -mediated negative regulation into positive fashion. In vitro EMSA suggested this wide
389 spaced TREs would favor TR monomer binding and strong TR interaction to the TREs particularly in the
390 presence of T_3 during differentiation. Ligand TR under differentiation appeared to suppress TK
391 transcription by creating a repressive chromatin environment and by reducing the recruitment of the
392 important transcription factor Sp1 to the promoter. This understanding of this complex regulation may have
393 implication to control alpha herpes virus infection and reactivation.

394 **Acknowledgement:**

395 This project is supported by R01NS081109 to SVH from NIH and the content is solely the responsibility
396 of the authors and does not necessarily represent the official views of the NINDS/NIH. The authors
397 appreciate the assistance of the editorial staff at UMES.

398

399 **Conflict of Interest**

Thyroid hormone mediated viral gene repression

400 The authors declare no conflict of interest.

401

402 **Author contributions**

403 RWF and SVH initiated this investigation and designed the study. FC provided the cultured cells. RWF
404 did all transfection experiments and analyzed the promoter activity. RWF performed the EMSA. FC
405 designed the primers and performed all the ChIP analyses. RWF performed the computational approach.
406 SVH wrote the original draft of the manuscript. RWF and FC contributed to portion of the manuscript
407 writing. All authors analyzed and validated the results and approved the final version of the manuscript.

408

409

410

411

412

413

414

415

416

417

418

419

420

421 **References:**

- 422 **Bedadala, G. R., Pinnoji, R. C., Palem, J. R. and Hsia, S. C.** (2010). Thyroid hormone controls the
423 gene expression of HSV-1 LAT and ICP0 in neuronal cells. *Cell Res* **20**, 587-98.
- 424 **Bendik, I. and Pfahl, M.** (1995). Similar ligand-induced conformational changes of thyroid
425 hormone receptors regulate homo- and heterodimeric functions. *J Biol Chem* **270**, 3107-14.
- 426 **Berghagen, H., Ragnhildstveit, E., Krogsrud, K., Thuestad, G., Apriletti, J. and Saatcioglu, F.**
427 (2002). Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a
428 negative hormone response element. *J Biol Chem* **277**, 49517-22.
- 429 **Burke, L. J., Zhang, R., Lutz, M. and Renkawitz, R.** (2002). The thyroid hormone receptor and the
430 insulator protein CTCF: two different factors with overlapping functions. *J Steroid Biochem Mol Biol* **83**,
431 49-57.
- 432 **Carr, F. E., Kaseem, L. L. and Wong, N. C.** (1992). Thyroid hormone inhibits thyrotropin gene
433 expression via a position-independent negative L-triiodothyronine-responsive element. *J Biol Chem* **267**,
434 18689-94.
- 435 **Chatterjee, V. K., Lee, J. K., Rentoumis, A. and Jameson, J. L.** (1989). Negative regulation of the
436 thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA
437 box. *Proc Natl Acad Sci U S A* **86**, 9114-8.
- 438 **Coen, D. M., Weinheimer, S. P. and McKnight, S. L.** (1986). A genetic approach to promoter
439 recognition during trans induction of viral gene expression. *Science* **234**, 53-9.
- 440 **Crone, D. E., Kim, H. S. and Spindler, S. R.** (1990). Alpha and beta thyroid hormone receptors
441 bind immediately adjacent to the rat growth hormone gene TATA box in a negatively hormone-
442 responsive promoter region. *J Biol Chem* **265**, 10851-6.
- 443 **Desai-Yajnik, V. and Samuels, H. H.** (1993). The NF-kappa B and Sp1 motifs of the human
444 immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response
445 elements. *Mol Cell Biol* **13**, 5057-69.
- 446 **Desvergne, B. and Favez, T.** (1997). The major transcription initiation site of the SV40 late
447 promoter is a potent thyroid hormone response element. *Nucleic Acids Res* **25**, 1774-81.
- 448 **Figliozzi, R. W., Chen, F., Balish, M., Ajavon, A. and Hsia, S. V.** (2014). Thyroid hormone-
449 dependent epigenetic suppression of herpes simplex virus-1 gene expression and viral replication in
450 differentiated neuroendocrine cells. *J Neurol Sci* **346**, 164-73.
- 451 **Hollenberg, A. N., Monden, T., Flynn, T. R., Boers, M. E., Cohen, O. and Wondisford, F. E.**
452 (1995). The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two
453 distinct classes of negative thyroid hormone response elements. *Mol Endocrinol* **9**, 540-50.
- 454 **Hsia, S. C., Bedadala, G. R. and Balish, M. D.** (2011). Effects of thyroid hormone on HSV-1 gene
455 regulation: implications in the control of viral latency and reactivation. *Cell Biosci* **1**, 24.
- 456 **Hsia, S. C., Pinnoji, R. C., Bedadala, G. R., Hill, J. M. and Palem, J. R.** (2010). Regulation of
457 herpes simplex virus type 1 thymidine kinase gene expression by thyroid hormone receptor in cultured
458 neuronal cells. *J Neurovirol* **16**, 13-24.
- 459 **Hsia, S. C. and Shi, Y. B.** (2002). Chromatin disruption and histone acetylation in regulation of
460 the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. *Mol Cell*
461 *Biol* **22**, 4043-52.
- 462 **Hsia, S. C., Tomita, A., Obata, K., Paul, B., Buchholz, D. and Shi, Y. B.** (2003). Role of chromatin
463 disruption and histone acetylation in thyroid hormone receptor action: implications in the regulation of
464 HIV-1 LTR. *Histol Histopathol* **18**, 323-31.
- 465 **Hsia, S. C., Wang, H. and Shi, Y. B.** (2001). Involvement of chromatin and histone acetylation in
466 the regulation of HIV-LTR by thyroid hormone receptor. *Cell Res* **11**, 8-16.
- 467 **Jacobs, G. F. and Kuhn, E. R.** (1992). Thyroid hormone feedback regulation of the secretion of
468 bioactive thyrotropin in the frog. *Gen Comp Endocrinol* **88**, 415-23.

- 469 **Johansson, M. U., Zoete, V., Michielin, O. and Guex, N.** (2012). Defining and searching for
470 structural motifs using DeepView/Swiss-PdbViewer. *BMC Bioinformatics* **13**, 173.
- 471 **Knipe, D. M. and Howley, P. M.** (2013). *Fields virology*. Philadelphia, PA: Wolters
472 Kluwer/Lippincott Williams & Wilkins Health.
- 473 **Kohn, L. D., Kosugi, S., Ban, T., Saji, M., Ikuyama, S., Giuliani, C., Hidaka, A., Shimura, H.,
474 Akamizu, T., Tahara, K. et al.** (1992). Molecular basis for the autoreactivity against thyroid stimulating
475 hormone receptor. *Int Rev Immunol* **9**, 135-65.
- 476 **Kosz-Vnenchak, M., Jacobson, J., Coen, D. M. and Knipe, D. M.** (1993). Evidence for a novel
477 regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons. *J Virol* **67**,
478 5383-93.
- 479 **Lalli, E. and Sassone-Corsi, P.** (1995). Thyroid-stimulating hormone (TSH)-directed induction of
480 the CREM gene in the thyroid gland participates in the long-term desensitization of the TSH receptor.
481 *Proc Natl Acad Sci U S A* **92**, 9633-7.
- 482 **Latif, R., Lau, Z., Cheung, P., Felsenfeld, D. P. and Davies, T. F.** (2016). The "TSH Receptor Glo
483 Assay" - A High-Throughput Detection System for Thyroid Stimulation. *Front Endocrinol (Lausanne)* **7**, 3.
- 484 **Lazar, M. A.** (1993). Thyroid hormone receptors: multiple forms, multiple possibilities. *Endocr
485 Rev* **14**, 184-93.
- 486 **Lin, C. K. and Chen, C. Y.** (2013). PiDNA: Predicting protein-DNA interactions with structural
487 models. *Nucleic Acids Res* **41**, W523-30.
- 488 **Luscombe, N. M., Laskowski, R. A. and Thornton, J. M.** (1997). NUCPLOT: a program to
489 generate schematic diagrams of protein-nucleic acid interactions. *Nucleic Acids Res* **25**, 4940-5.
- 490 **Luscombe, N. M., Laskowski, R. A., Westhead, D. R., Milburn, D., Jones, S., Karmirantzou, M.
491 and Thornton, J. M.** (1998). New tools and resources for analysing protein structures and their
492 interactions. *Acta Crystallogr D Biol Crystallogr* **54**, 1132-8.
- 493 **Madison, L. D., Ahlquist, J. A., Rogers, S. D. and Jameson, J. L.** (1993). Negative regulation of
494 the glycoprotein hormone alpha gene promoter by thyroid hormone: mutagenesis of a proximal
495 receptor binding site preserves transcriptional repression. *Mol Cell Endocrinol* **94**, 129-36.
- 496 **Maia, A. L., Harney, J. W. and Larsen, P. R.** (1996). Is there a negative TRE in the luciferase
497 reporter cDNA? *Thyroid* **6**, 325-8.
- 498 **Matsushita, A., Sasaki, S., Kashiwabara, Y., Nagayama, K., Ohba, K., Iwaki, H., Misawa, H.,
499 Ishizuka, K. and Nakamura, H.** (2007). Essential role of GATA2 in the negative regulation of thyrotropin
500 beta gene by thyroid hormone and its receptors. *Mol Endocrinol* **21**, 865-84.
- 501 **Mendez-Pertuz, M., Sanchez-Pacheco, A. and Aranda, A.** (2003). The thyroid hormone receptor
502 antagonizes CREB-mediated transcription. *EMBO J* **22**, 3102-12.
- 503 **Nichol, P. F., Chang, J. Y., Johnson, E. M., Jr. and Olivo, P. D.** (1996). Herpes simplex virus gene
504 expression in neurons: viral DNA synthesis is a critical regulatory event in the branch point between the
505 lytic and latent pathways. *J Virol* **70**, 5476-86.
- 506 **Nygaard, M., Wahlstrom, G. M., Gustafsson, M. V., Tokumoto, Y. M. and Bondesson, M.** (2003).
507 Hormone-dependent repression of the E2F-1 gene by thyroid hormone receptors. *Mol Endocrinol* **17**,
508 79-92.
- 509 **Park, H. Y., Davidson, D., Raaka, B. M. and Samuels, H. H.** (1993). The herpes simplex virus
510 thymidine kinase gene promoter contains a novel thyroid hormone response element. *Mol Endocrinol* **7**,
511 319-30.
- 512 **Pesola, J. M., Zhu, J., Knipe, D. M. and Coen, D. M.** (2005). Herpes simplex virus 1 immediate-
513 early and early gene expression during reactivation from latency under conditions that prevent
514 infectious virus production. *J Virol* **79**, 14516-25.
- 515 **Rastinejad, F., Huang, P., Chandra, V. and Khorasanizadeh, S.** (2013). Understanding nuclear
516 receptor form and function using structural biology. *J Mol Endocrinol* **51**, T1-T21.

Thyroid hormone mediated viral gene repression

- 517 **Rastinejad, F., Perlmann, T., Evans, R. M. and Sigler, P. B.** (1995). Structural determinants of
518 nuclear receptor assembly on DNA direct repeats. *Nature* **375**, 203-11.
- 519 **Rentoumis, A., Chatterjee, V. K., Madison, L. D., Datta, S., Gallagher, G. D., Degroot, L. J. and**
520 **Jameson, J. L.** (1990). Negative and positive transcriptional regulation by thyroid hormone receptor
521 isoforms. *Mol Endocrinol* **4**, 1522-31.
- 522 **Sanchez-Pacheco, A. and Aranda, A.** (2003). Binding of the thyroid hormone receptor to a
523 negative element in the basal growth hormone promoter is associated with histone acetylation. *J Biol*
524 *Chem* **278**, 39383-91.
- 525 **Sasaki, S., Lesoon-Wood, L. A., Dey, A., Kuwata, T., Weintraub, B. D., Humphrey, G., Yang, W.**
526 **M., Seto, E., Yen, P. M., Howard, B. H. et al.** (1999). Ligand-induced recruitment of a histone
527 deacetylase in the negative-feedback regulation of the thyrotropin beta gene. *EMBO J* **18**, 5389-98.
- 528 **Shibusawa, N., Hollenberg, A. N. and Wondisford, F. E.** (2003). Thyroid hormone receptor DNA
529 binding is required for both positive and negative gene regulation. *J Biol Chem* **278**, 732-8.
- 530 **Tagami, T., Park, Y. and Jameson, J. L.** (1999). Mechanisms that mediate negative regulation of
531 the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. *J Biol Chem* **274**, 22345-
532 53.
- 533 **Tal-Singer, R., Eisenberg, R. J., Valyi-Nagy, T., Fraser, N. W. and Cohen, G. H.** (1994). N-linked
534 oligosaccharides on herpes simplex virus glycoprotein gD are not essential for establishment of viral
535 latency or reactivation in the mouse eye model. *Virology* **202**, 1050-3.
- 536 **Tal-Singer, R., Lasner, T. M., Podrzucki, W., Skokotas, A., Leary, J. J., Berger, S. L. and Fraser, N.**
537 **W.** (1997). Gene expression during reactivation of herpes simplex virus type 1 from latency in the
538 peripheral nervous system is different from that during lytic infection of tissue cultures. *J Virol* **71**, 5268-
539 76.
- 540 **Valyi-Nagy, T., Gesser, R. M., Raengsakulrach, B., Deshmane, S. L., Randazzo, B. P., Dillner, A. J.**
541 **and Fraser, N. W.** (1994). A thymidine kinase-negative HSV-1 strain establishes a persistent infection in
542 SCID mice that features uncontrolled peripheral replication but only marginal nervous system
543 involvement. *Virology* **199**, 484-90.
- 544 **Villa, A., Santiago, J., Belandia, B. and Pascual, A.** (2004). A response unit in the first exon of the
545 beta-amyloid precursor protein gene containing thyroid hormone receptor and Sp1 binding sites
546 mediates negative regulation by 3,5,3'-triiodothyronine. *Mol Endocrinol* **18**, 863-73.
- 547 **Wilcox, C. L., Crnic, L. S. and Pizer, L. I.** (1992). Replication, latent infection, and reactivation in
548 neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. *Virology* **187**, 348-52.
- 549 **Xu, J., Thompson, K. L., Shephard, L. B., Hudson, L. G. and Gill, G. N.** (1993). T3 receptor
550 suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via
551 overlapping DNA-binding sites. *J Biol Chem* **268**, 16065-73.
- 552 **Yen, P. M.** (2001). Physiological and molecular basis of thyroid hormone action. *Physiol Rev* **81**,
553 1097-142.
- 554 **Zuo, F., Kraus, R. J., Gulick, T., Moore, D. D. and Mertz, J. E.** (1997). Direct modulation of simian
555 virus 40 late gene expression by thyroid hormone and its receptor. *J Virol* **71**, 427-36.
- 556
557
558
559
560
561
562
563
564

565 **Table 1. Antibodies**

Peptide/Protein Target	Name of Antibody	Manufacturer, Catalog No., or Name of Source	Species Raised in Monoclonal or Polyclonal	Dilution Used
THRA from human, mouse, rat, amphibian, avian, chicken, non-human primate, <i>Xenopus laevis</i> NULL	Mouse Anti-Thyroid Hormone Receptor Monoclonal Antibody, Unconjugated, Clone C3	Thermo Fisher, MA1-215	Mouse, monoclonal	1:20
Retinoic Acid Receptor alpha antibody [H1920] - ChIP Grade human, human	Retinoic Acid Receptor alpha antibody [H1920] - ChIP Grade	Abcam, ab41934	Mouse, monoclonal	1:20
Histone H3 (tri methyl K9) - ChIP Grade bovine, canine, chicken/avian, donkey, drosophila, feline, guinea pig, hamster, horse, human, mouse, other, porcine, rabbit, rat, sheep, simian, xenopus, yeast, this antibody reacts with tri methylated k9 within a sequence found in all mammals and a wide range of other species, including arabidopsis, s pombe, n crassa, aspergillus nidulans, d melanogaster, saccharomyces cerevisiae (pubmed 17371840) s ocellaris, c reinhardtii, c elegans, xenopus, chicken, zebrafish and tobacco the antibody will react with any species where the modification is present reacts with human, mouse, rat and indian muntjac	Rabbit Anti-Histone H3, trimethyl (Lys9) ChIP Grade Polyclonal Antibody, Unconjugated	Abcam, ab8898	Rabbit, polyclonal	1:20
Sp1 (PEP 2) mouse, rat, human, mouse, rat, human	Sp1 (PEP 2) antibody	Santa Cruz, sc-59	Rabbit, polyclonal	1:20

566

567

568

569

570 **Figure Legend:**

571 **Fig. 1: Computational analysis to predict binding of nuclear receptor to putative TK TREs**

572 The interactions of protein and DNA were investigated by PiDNA, a web based application,
573 to interpret the results from the biochemical assays. The high-scored putative TRE half-sites were
574 further assessed for hydrogen bond interactions using Python Molecule Viewer (PMV) software
575 and PDBSum. PMV was used to visualize and measure distances between the DNA binding
576 protein residues and the bases of the DNA TRE half-sites. PDBSum calculates and diagrams
577 putative hydrogen bonds between the DNA and the Protein in the pdb files.

578 A. Random screening of PiDNA identified 5'-AGGTGA-3' (TRE-1a) on the positive strand and
579 5'-AGGCCA-3' (TRE-2) located at the reverse strand of the HSV-1 TK promoter as the best
580 half-sites for protein binding. The orientation of these half-sites for TRE-1 and TRE-2 was
581 suggested as palindromic TREs with a six nucleotide in between (Pal 6). The point mutation
582 changed the TRE-1a to 5'-AGGTGC-3' and TRE-1b to 5'-GCGGCA-3' on the reverse
583 strand. This shift would allow TRE-1b' and TRE-2 to form a direct repeat separated by three
584 nucleotides (DR 3), presumably to generate positive regulation.

585 B. PDBSum hydrogen bonding analysis of TR β and RXR α hydrogen bonding to 5'-AGGTGA-
586 3' (wt TRE-1a), 5'-AGGTGC-3' (mt TRE-1a'), and 5'-GCGGCA-3' (mt TRE-1b') suggested
587 strongest binding to TRE-1b' after the mutation due to one more hydrogen bond established
588 from Arg160 of the RXR α .

589

590

591


592

593

594

595

Thyroid hormone mediated viral gene repression



596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

Thyroid hormone mediated viral gene repression

611 **Fig. 2: Site-directed mutagenesis**

- 612 A. HSV-1 TK TREs and sequences of the mutant TREs. A 32-base of HSV-1 TK promoter regions
613 from TATA box through the transcription initiation site was shown. The TATA box is framed
614 and bases matching TRE half-site consensus sequences are identified by asterisks (*). TRE half-
615 site directions are identified by arrows. TREs are described and classified in reference to the well
616 described TRE consensus sequence AGGT(G/C)A. The wt HSV-1 TK TRE is described as a
617 palindrome with 6-nucleotide spacing (Pal6).
- 618 B. Mutagenesis strategy. Specific primers were designed to introduce the mutation into the precise
619 position using Phusion Site-Directed Mutagenesis system.




Fig. 2

620

621

622

623

624

625

Thyroid hormone mediated viral gene repression

626 **Fig. 3: Transfection and DLuc assays**

- 627 A. Transfection of undifferentiated cells. Dual-Luciferase assays of undifferentiated LNCaP cells
628 transfected with HSV-1 TK TRE luciferase reporter plasmids: wtPal6 and mtTRE treated with
629 and without T₃, were performed in triplicate. The effects of T₃ on promoter activity were not
630 significant and wt promoter generally had stronger activity in comparison to mt counterpart. Two-
631 way ANOVA with Holm-Sidak post-hoc analysis suggests that the differences in activity is not
632 significant.
- 633 B. Transfection of differentiated cells. Similar Dual-Luciferase assays of differentiated LNCaP cells
634 transfected with the reporter plasmids in the presence or absence of T₃, were done in triplicate. It
635 appeared that mt plasmids exhibited different T₃ -mediated regulation compared to the wt version.
636 Two-way ANOVA with Holm-Sidak posthoc analysis suggests that the differences in activity is
637 statistically significant where * denotes p<0.05.

638




Fig. 3

639

640

Thyroid hormone mediated viral gene repression

641 **Fig. 4: EMSA**

- 642 A. The labeled wt TRE oligo was incubated with differentiated protein extract without hormone
643 pretreatment followed by gel electrophoresis and the image was captured. Lane 1, no protein;
644 Lane 2-7, incubated with protein extract from differentiated cells; Lane 4-5, with anti-TR β Ab;
645 Lane 6-7, with anti-RXR α Ab. The image came from a 10-well 6% DNA Retardation Gel.
- 646 B. Undifferentiated protein extract was used for comparison. It is shown that TRE-TR interaction
647 was not seen in undifferentiated extract. Both wtTRE (lane 2-7) and mtTRE1 (lane 10-15) failed
648 to interact with TR. positive control was wtTRE interacted with differentiated protein extract
649 without T₃ pretreatment, like Fig. 4A, lane 2. Note that this gel had 15-well so the bands were not
650 as sharp as the other gels, which were 10-well gels.
- 651 C. The comparison of TREs oligo/TR interaction with or without T₃ pretreatment was analyzed.
652 Lane 2-3, extract without T₃ pretreatment. Lane 4-7, extract with prior T₃ pretreatment. It
653 appeared that TRE/TR interaction increased in the presence of T₃ with hormone pretreatment
654 (compare lane 4 and 5). Anti-TR Ab failed to completely abolish the interaction (lane 6 and 7),
655 suggesting a robust binding of TR to TRE in T₃. The free oligos were run out of the gel due to
656 increased electrophoresis time to improve the resolution.
- 657 D. The interaction of mutant TRE1 to TR with pretreatment was investigated. Lane 1, no extract;
658 Lane 2 and 4, no T₃; Lane 3 and 5, with T₃; Lane 4-5, anti-TR Ab added. The intensity of
659 mtTRE1 was reduced in the presence of T₃ (compare lane 2 and 3). Anti-TR Ab addition did not
660 alter the interaction (lanes 4 and 5). Anti-RXR Ab addition altered the interaction (lanes 6 and 7).
661 The free oligos were not seen because of elongated electrophoresis.

662

663

664

665

666

Thyroid hormone mediated viral gene repression




Fig. 4

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

Thyroid hormone mediated viral gene repression

682 **Fig. 5a: Enrichment of repressive chromatin H3K9me3 at the HSV-1 TK TREs**

683 ChIP assay measuring the enrichment of H3K9me3, a repressive chromatin protein marker, to
684 HSV-1 TK TREs from differentiated LNCaP cells transfected with wtTRE and mtTRE1 treated
685 with and without T₃ presented as percent input with IgG background subtracted. T₃
686 treatment of wtTRE resulted in a 4.5-fold increase in comparison to no T₃ treatment. The
687 mtTRE1, however, showed an opposite effect where T₃ treatment caused a reduction.

688

689 **Fig. 5b: Recruitment of Sp1 to the TK TREs**

690 The occupancy of transcription factor Sp1 to HSV-1 TK TREs under the influence of T₃ was
691 analyzed by ChIP from differentiated LNCaP cells transfected with wtTRE and mtTRE1. The
692 results were presented as percent input with IgG background subtracted. For the wtTREs the T₃
693 treatment resulted in a 4-fold reduction of Sp1 recruitment comparing to no T₃ treatment. The
694 mtTRE1 showed a reversed effect that T₃ increased the Sp1 occupancy in comparison to no T₃.




Fig. 5

695